Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis

An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of SBI-087 Administered To Japanese Subjects With Rheumatoid Arthritis

The purpose of this study is to evaluate the safety and tolerability of single doses of SBI-087 in Japanese subjects with rheumatoid arthritis.

Inclusion Criteria:

• Must meet American College of Rheumatology criteria for rheumatoid arthritis with functional class I to III.
• Rheumatoid arthritis disease onset at >16 years of age and duration of disease at least 6 months.
• Men or women of nonchildbearing potential (WONCBP), aged 20 to 70 years, inclusive at the screening visit.

Exclusion Criteria:

• Any significant health problems other than rheumatoid arthritis.
• Treatment of greater than 10 mg of prednisone per day.
• Therapy with immunosuppressants within 6 months before study day 1